# Isosorbide Mononitrate and Butylphthalide to Reduce the Risk of Disability in Patients With Acute Lacunar Stroke (IMPACT)

> **NCT07252544** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Beijing Tiantan Hospital** · enrollment: 3156 (estimated)

## Conditions studied

- Stroke, Lacunar
- Stroke, Acute Ischemic
- Cerebral Small Vessel Diseases

## Interventions

- **DRUG:** Isosorbide Mononitrate
- **DRUG:** Butylphthalide
- **DRUG:** Isosorbide Mononitrate Placebo
- **DRUG:** Butylphthalide Placebo

## Key facts

- **NCT ID:** NCT07252544
- **Lead sponsor:** Beijing Tiantan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2027-08-31
- **Final completion:** 2028-02-29
- **Target enrollment:** 3156 (ESTIMATED)
- **Last updated:** 2025-11-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07252544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07252544, "Isosorbide Mononitrate and Butylphthalide to Reduce the Risk of Disability in Patients With Acute Lacunar Stroke (IMPACT)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07252544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*